ANVS-301 is under clinical development by Annovis Bio and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ANVS-301’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ANVS-301 is under development for the treatment of cognitive capability in later stages of Alzheimer’s disease and dementia. It is administered through the oral route. It acts by targeting the butyrylcholinesterase (BuChE) enzyme.
Annovis Bio overview
Annovis Bio is a clinical-stage drug platform company that carries out the development of novel drugs for the treatment of various diseases. The company’s pipeline products include buntanetap, to treat parkinson’s disease (PD), alzheimer’s disease (AD), and other chronic neurodegenerative diseases; ANVS405, to treat traumatic brain injury (TBI) and stroke; ANVS301, to treat advanced alzheimer’s disease. It provides drug candidates in oral and injectable forms. Annovis Bio also carries out preclinical animal studies and clinical trials. The company collaborates with contractor laboratories, independent contractors and contract research organizations. Annovis Bio is headquartered in Berwyn, Pennsylvania, the US.
For a complete picture of ANVS-301’s drug-specific PTSR and LoA scores, buy the report here.